Prolongation of survival time and improvement of the quality of life after treatment with irinotecan liposomal in the patient with metastatic pancreatic adenocarcinoma Case report

Main Article Content

Wojciech Rogowski
Przemysław Będkowski

Abstract

Pancreatic cancer is one of the malignant neoplasms with the worst prognosis. It is most often diagnosed at an advanced stage, which relates to unsatisfactory results of the therapy. Only about 15–20% of patients with pancreatic cancer qualify for surgery. The remaining patients are diagnosed with locally advanced disease or much more frequently in the generalized stage. Systemic treatment (chemotherapy) remains the mainstay of therapy in these patients, but both the response rate and progression-free time are unsatisfactory [1, 2].


This paper presents a case of a patient with metastatic pancreatic cancer, in whom three lines of systemic treatment were applied sequentially, which allowed to extend the survival time and improve the quality of life.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Article Details

How to Cite
1.
Rogowski W, Będkowski P. Prolongation of survival time and improvement of the quality of life after treatment with irinotecan liposomal in the patient with metastatic pancreatic adenocarcinoma. OncoReview [Internet]. 2021Jul.15 [cited 2021Nov.28];11(3(43):77-9. Available from: https://journalsmededu.pl/index.php/OncoReview/article/view/1519
Section
PERSONALIZED ONCOLOGY

References

1. Vincent A, Herman J, Schulick R et al. Pancreatic cancer. Lancet. 2011; 378(9791): 607-20.
2. McGuigan A, Kelly P, Turkington RC et al. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018; 24(43): 4846-61. http://doi.org/10.3748/wjg.v24.i43.4846.
3. Wojciechowska U, Didkowska J. Zachorowania i zgony na nowotwory złośliwe w Polsce. Krajowy Rejestr Nowotworów, Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie – Państwowy Instytut Badawczy (access: 1.03.2021).
4. Martín AM, Hidalgo M, Alvarez R et al. From First Line to Sequential Treatment in the Management of Metastatic Pancreatic Cancer. J Cancer. 2018; 9(11): 1978-88. http://doi.org/10.7150/jca.23716.
5. Von Hoff DD, Ervin T, Arena FP et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013; 369: 1691-703.
6. Wang-Gillam A, Hubner RA, Siveke JT et al. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors. Eur J Cancer. 2019; 108: 78-87.